Al-Aalim, A., Hamad, M., AL-ledani, A. (2020). Some insights of novel COVID 19 virus: structure, pathogenicity and immunity aspects. Alustath, 34(2), 287-293. doi: 10.33899/ijvs.2020.126898.1408
Ammar M. Al-Aalim; Mohammad A. Hamad; Ali A. AL-ledani. "Some insights of novel COVID 19 virus: structure, pathogenicity and immunity aspects". Alustath, 34, 2, 2020, 287-293. doi: 10.33899/ijvs.2020.126898.1408
Al-Aalim, A., Hamad, M., AL-ledani, A. (2020). 'Some insights of novel COVID 19 virus: structure, pathogenicity and immunity aspects', Alustath, 34(2), pp. 287-293. doi: 10.33899/ijvs.2020.126898.1408
Al-Aalim, A., Hamad, M., AL-ledani, A. Some insights of novel COVID 19 virus: structure, pathogenicity and immunity aspects. Alustath, 2020; 34(2): 287-293. doi: 10.33899/ijvs.2020.126898.1408

Some insights of novel COVID 19 virus: structure, pathogenicity and immunity aspects

Iraqi Journal of Veterinary Sciences
Article 11, Volume 34, Issue 2, July 2020, Pages 287-293    PDF (643.81 K)
DOI: 10.33899/ijvs.2020.126898.1408
Authors
Ammar M. Al-Aalim* 1; Mohammad A. Hamad2; Ali A. AL-ledani3
1Department of Microbiology, College of Veterinary Medicine, University of Mosul, Mosul, Iraq.
2Department of Microbiology, College of Veterinary Medicine. University of Mosul, Mosul, Iraq
3Department of Microbiology, College of Veterinary Medicine, University of Basrah, Basrah, Iraq
Abstract
COVID- 19 is highly infectious disease where the first infected case reported in Wuhan city-China, then it was spread worldwide. The causative agent belongs to novel enveloped single linear positive-sense stranded RNA Coronavirus, which is also called SARS-CoV-2 and has an affinity to lung cells. The genetic analysis of SARS-CoV-2 suggested that this novehtm hgn l strain may be developed from the animal. origin by recombination between a bat SARS-like CoV and a coronavirus of unknown origin. The ability of rapid spread of SARS-CoV-2 virus from person to other is similar or even more than to other human viruses like influenza or plague leadding to be announced as a pandemic by WHO in 2020. The mortality rate in SARS-CoV-2 increased day by day and this led the scientists to search ways to control the virus. Most of the deaths in aged patients may be due to immune response complications where 70% of patients showed lymphopenia. This review, provided some details about structure, pathogenicity and immune response against SARS-CoV-2. The facts in this review lead to suggest that in most cases the death in SARS-CoV-2 may occur via loss of systemic inflammatory response control which leading to lung injury followed by pneumonia, acute respiratory distress syndrome (ARDS) and respiratory failure, hence the death especially in old patients. In concluding the early effective control of both innate and adaptive immunity may be the critical. key factor in protection against SARS-CoV-2.

Highlights

This scientific review highlighted on the pathological and immunological properties of SARS-CoV-2 virus, as well as the genetic makeup of the virus, reasonable explanations for the causes of prevalence in old age groups and the causes of death with this disease while highlighting the role of innate and acquired immunity in fighting this disease.

Keywords
SARS-CoV-2; ARDS; Coronavirus; MERS-CoV
References
  1. https://www.who.int/emergencies/diseases/novel-coronavirus-2019
  2. Iraq ministry of public health https://moh.gov.iq/index.php?name= News&file=article& sid=14319
  3. Jiang F, Deng L, Zhang L, Cai Y, Cheung CW, Xia Z. Review of the clinical. characteristics of coronavirus disease 2019 (COVID-19). J Gen Intern Med. 2020;26.:1-5. Doi: 10.1007/s11606-020-05762-w.
  4. Deng CX. The global. battle against SARS-CoV-2 and COVID-19. Int J Biol Sci. 2020;16(10):1676-1677. Doi:10.7150/ijbs.45587.
  5. Murphy AF, Gibbs EPJ, Horzinek CM, Studdert JM.Vet Virol. 3rd ed. San Diego: Academic Press Elsevier; 1999. 495-509,127-161 p. https://www.elsevier.com/books/veterinary-virology/murphy/978-0-12-511340-3
  6. Carter BJ, Saunders AV. Virology principle and application. 2st ed. England: John Wiley; 2007. 103-114 p. https://www.wiley.com/en-us/Virology%3A+Principles+and+Applications%2C+2nd+Edition-p-9781119991427
  7. MacLachlan JN, Dubovi JE. Fenner’s veterinary virology. 4th ed. London: Academic Press; 2016. 75-100,393-419 p. Doi:10.1016/C2013-0-06921-6>
  8. Ashour HM, Elkhatib WF, Rahman M, Elshabrawy HA. Insights into the recent 2019 novel coronavirus (SARS-CoV-2) in light of past human coronavirus outbreaks. Pathogens. 2020;9(3):186. Doi:10.3390/pathogens9030186.
  9. Drosten C, Günther S, Preiser W, Van der WS, Brodt H, Becker S, Rabenau H, Panning M, Kolesnikova L, Fouchier RA M, Berger A, Burguière A, Cinatl J, Eickmann M, Escriou N, Müller GK, Kramme S, Manuguerra J, Rickerts V, Stürmer M, Vieth S, Klenk H, Osterhaus AD, Schmitz H, Doerr WH. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med. 2003;348(20):1967-1976. Doi:10.1056/NEJMoa030747
  10. Zaki AM, Van Boheemen S, Bestebroer TM, Osterhaus AD, Fouchier RA. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med. 2012;367(19):1814-1820. Doi:10.1056/NEJMoa1211721.
  11. Lorusso A, Calistri P, Petrini A, Savini G, Decaro N. Novel coronavirus (SARS-CoV-2) epidemic: A veterinary perspective. Vet Ital. 2020;12:1-6. Doi:10.12834/VetIt.2173.11599.1.
  12. Shereen MA, Khan S, Kazmi A, Bashir N, Siddique R. COVID-19 infection: Origin, transmission, and characteristics of human coronaviruses. J Adv Res. 2020;15.:91-98. Doi:10.1016/j.jare.2020.03.005.
  13. Han Y, Yang H. The transmission and diagnosis of 2019 novel coronavirus infection disease (COVID‐19): A Chinese perspective. J Med Virol. 2020;92(6):634-644. Doi:10.1002/jmv.25749.
  14. Van Doremalen N, Bushmaker T, Morris HD, Holbrook GM, Gamble A, Williamson NB, Tamin A, Harcourt LJ, Thornburg JN, Gerber IS, Lloyd-Smith OJ, De Wit E, Munster JV. Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1.N Engl J Med. 2020; 382 (16):1564-1567. Doi:10.1056/NEJMc2004973.
  15. Lo IL, Lio CF, Cheong HH, Lei CI, Cheong TH, Zhong X, Tian Y, Sin NN. Evaluation of SARS-CoV-2 RNA shedding in clinical. specimens and clinical. characteristics of 10 patients with COVID-19 in Macau. Int J Biol Sci. 2020;16(10):1698-707. Doi:10.7150/ijbs.45357.
  16. Lu C, Liu X, Jia Z. 2019-nCoV transmission through the ocular surface must not be ignored. Lancet. 2020;395(10224): e39. Doi:10.1016/S0140-6736(20)30313-5.
  17. Peng X, Xu X, Li Y. Cheng L, Zhou X, Ren B. Transmission routes of 2019-nCoV and controls in dental. practice. Int J Oral. Sci. 2020;12(9):1-5. Doi:10.1038/s41368-020-0075-9.
  18. Bai Y, Yao L, Wei T, Tian F, Jin D, Chen L, Wang M. Presumed asymptomatic carrier transmission of COVID-19. JAMA. 2020; 323(14):1406-1407. Doi:10.1001/jama.2020.2565.
  19. Al-Tawfiq AJ. Asymptomatic coronavirus infection: MERS-CoV and SARS-CoV-2 (COVID-19). Travel Med Infect Dis. 2020;27: 101608:1-2. Doi:10.1016/j.tmaid.2020.101608.
  20. Carrasco-Hernandez R, Jácome R, López Vidal. Y, Ponce de León S. Are RNA viruses candidate agents for the next global. pandemic? A review. ILAR J. 2017;58(3):343-358. Doi:10.1093/ilar/ilx026.
  21. Lu R, Zhao X, Li J, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020; 395(10224):565-574. doi:10.1016/S0140-6736(20)30251-8.
  22. Zhang C, Zheng W, Huang X, Bell W. E., Zhou X, Zhang Y. Protein Structure and Sequence Reanalysis of 2019-nCoV Genome Refutes Snakes as Its Intermediate Host and the Unique Similarity between Its Spike Protein Insertions and HIV‑1. J Proteome Res. 2020;19: 1351−1360. Doi:10.1021/acs.jproteome.0c00129.
  23. Rabi AF, Al. Zoubi SM, Kasasbeh AG, Salameh MD, Al-Nasser DA. SARS-CoV-2 and coronavirus disease 2019: What we know so far. Pathogens. 2020;9(3):231. Doi:10.3390/pathogens9030231.
  24. Tang X, Wu C, Li X, Song Y, Yao X, Wu X, Duan Y, Zhang H, Wang Y, Qian Z, Cui J. On the origin and continuing evolution of SARS-CoV-2. Nat Sci Rev. 2020;nwaa036:1-26. Doi:10.1093/nsr/nwaa036.
  25. Coutard B, Valle C, de Lamballerie X, Canard B, Seidah NG, Decroly E. The spike glycoprotein of the new coronavirus 2019- ,,nCoV contains a furin-like cleavage site absent in CoV of the same clade. Antiviral. Res. 2020;1(176):104742. Doi:10.1016/j.antiviral.2020.104742.
  26. Wrapp D, Wang N, Corbett KS.,Goldsmith JA, Hsieh CL, Abiona O, Graham BS, McLellan JS. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Sci. 2020;367:1260-1263. Doi:10.1126/science.abb250.
  27. Rothe C, Schunk M, Sothmann P, Bretzel G, Froeschl G, Wallrauch C, Zimmer T, Thiel, Janke C, Guggemos W, Seilmaier M, Drosten C, Vollmar P, Zwirglmaier K, Zange S, Wölfel R, Hoelscher M. Transmission of 2019-nCoV infection from an asymptomatic contact in Germany. N Engl J Med. 2020;382(10):970-971. Doi:10.1056/NEJMc2001468.
  28. Prompetchara E, Ketloy C, Palaga T. Immune responses in COVID-19 and potential. vaccines: Lessons learned from SARS and MERS epidemic. Asian Pac J Allergy Immunol. 2020;38(1):1-9. Doi:10.12932/AP-200220-0772.
  29. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B. Clinical. features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506. Doi:10.1016/S0140-6736(20)30183-5.
  30. Kikkert M. Innate immune evasion by human respiratory RNA viruses. J Innate Immun. 2020;12(1):4-20. Doi:10.1159/000503030.
  31. Li G, Fan Y, Lai Y, Han T, Li Z, Zhou P, Pan P, Wang W, Hu D, Liu X, Zhang Q. Coronavirus infections and immune responses. J Med Virol. 2020;92(4):424-32. Doi:10.1016/j.tmaid.2020.101575.
  32. Li X, Geng M, Peng Y, Meng L, Lu S. Molecular immune pathogenesis and diagnosis of COVID-19. J Pharmaceut Anal. 2020;5:1-7. Doi:10.1016/j.jpha.2020.03.001.
  33. Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, Liu S, Zhao P, Liu H, Zhu L, Tai Y. Pathological. findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Res Med. 2020; 8(4):420-422. Doi:10.1016/S2213-2600(20)30076-X.
  34. Nezhad SF, Mosaddeghi P, Negahdaripour M, Dehghani Z, Farahmandnejad M, Moghadami M, Nezafat N, Masoompour S M. Therapeutic approaches for COVID-19 Based on the dynamics of interferon-mediated immune responses. Preprints. 2020; 2020030206. Doi:10.20944/preprints202003.0206.v1.
  35. Bao L, Deng W, Gao H, Xiao C, Liu J, Xue J, Lv Q, Liu J, Yu P, Xu Y, Qi F. Reinfection could not occur in SARS-CoV-2 infected rhesus macaques.  bioRxiv. 2020;1. Doi:10.1101/2020.03.13.990226,2020.
  36. Dong C, Ni L, Fang Ye, Meng-Li C, Yu F, Yong-Qiang D, Hui Z, Peng W, Jiwan G, Xiaoli L, Lin, Pengzhi W, Peng L, Han G, Xinquan W, Cheng-Feng Q. Characterization of anti-viral. immunity in recovered individuals infected by SARS-CoV-2. medRxiv. 2020;17. Doi:10.1101/2020.03.17.20036640.
  37. Tan L, Wang Q, Zhang D, Ding J, Huang Q, Tang YQ, Wang Q, Miao H. Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study. Signal. Transduct Target Ther. 2020; 5(33):1-3. Doi:10.1038/s41392-020-0148-4.
  38. Zeng Q, Li YZ, Huang G, Wu W, Dong SY, Xu Y. Mortality of COVID-19 is associated with cellular immune function compared to immune function in chinese han population. medRxiv. 2020;1. Doi:10.1101/2020.03.08.20031229.
  39. Chen X, Ling J, Mo P, Zhang Y, Jiang Q, Ma Z, Cao Q, Hu W, Zou S, Chen L, Yao L. Restoration of leukomonocyte counts is associated with viral. clearance in COVID-19 hospitalized patients. medRxiv. 2020;1. Doi:10.1101/2020.03.03.20030437.
  40. Lin L, Lu L, Cao W, Li T. Hypothesis for potential. pathogenesis of SARS-CoV-2 infection--a review of immune changes in patients with viral. pneumonia. Emerg Microbes Infect. 2020; 9(1):727-732. Doi:10.1080/22221751.2020.1746199.
  41. Xie J, Fan HW, Li TS, Qiu ZF, Han Y. Dynamic changes of T lymphocyte subsets in the long-term follow-up of severe acute respiratory syndrome patients. Act Acad Med Sci. 2006;28(2):253-255. http://www.actacams.com/EN/Y2006/V28/I2/253 or https://pubmed.ncbi.nlm.nih.gov/16733915
  42. Wang D, Hu B, Hu C, Clinical. Characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020;323(11):1061-1069. Doi:10.1001/jama.2020.1585.
  43. Zhou Y, Fu B, Zheng X, Wang D, Zhao C, Sun R, Tian Z, Xu X, Wei H. Pathogenic T cells and inflammatory monocytes incite inflammatory storm in severe COVID-19 patients. Nat Sci Rev. 2020; 13.nwaa041:1-15. Doi:10.1093/nsr/nwaa041.
  44. Chen C, Qi F, Shi K, Li Y, Li J, Chen Y, Pan J, Zhou T, Lin X, Zhang J, Luo Y, Li X, Xia J. Thalidomide combined with low-dose glucocorticoid in the treatment of COVID-19 pneumonia.  Preprints allergology. 2020;2020020395. https://www.preprints.org/ manuscript/202002.0395/v1
  45. Diao B, Wang C, Tan Y, Chen X, Liu Y, Ning L, Chen L, Li M, Liu Y, Wang G, Yuan Z. Reduction and functional. exhaustion of T cells in patients with coronavirus disease 2019 (COVID-19). medRxiv. 2020;1.  Doi:10.1101/2020.02.18.20024364.
  46. Zheng H, Zhang M, Yang C, Zhang N, Wang X, Yang X, Dong X, Zheng Y. Elevated exhaustion levels and reduced functional. diversity of T cells in peripheral. blood may predict severe progression in COVID-19 patients. Cell Mol Immunol. 2020;17:1-3 Doi:10.1038/s41423-020-0401-3.
  47. Zheng M, Gao Y, Wang G, Song G, Liu S, Sun D, Xu Y, Tian Z. Functional. exhaustion of antiviral. lymphocytes in COVID-19 patients. Cell Mol Immunol. 2020;19:1-3. Doi:10.1038/s41423-020-0402-2.
Statistics
Article View: 3,336
PDF Download: 1,971


Journal Management System. Powered by ejournalplus.com